Abstract 2193
Background
Despite existing clinical guidelines on bone health in patients with cancer (ESMO 2014), the use of recommended BTA is sub-optimal for many patients. It is unclear if physicians’ decisions are aligned with ESMO’s guidelines to initiate BTA as soon as bone metastasis (BM) are diagnosed, irrespective of symptomatic disease, in breast cancer (BC) or castration-resistant prostate cancer (CRPC) patients. The current study describes BTA initiation in BC or CRPC patients with BM treated within routine clinical settings.
Methods
Data reported by physicians (oncologists or urologists) in Europe via online data capture using physician-directed surveys and patients’ medical records as required were analysed. Adult BC or physician-defined CRPC patients included in the study received active anti-cancer treatment between February 2015 and April 2015. Adherence to the ESMO 2014 guidelines was defined as the proportion of patients with a BTA initiation within 3 months (<90 days) of BM diagnosis.
Results
A total of 731 physicians reported data on 1,857 patients treated for their cancer in Europe. For BC patients (n = 1,195) and CRPC patients (n = 662) treated by oncologists, only 84% and 61%, respectively, received their first BTA within 3 months of BM diagnosis. Adherence to the ESMO 2014 guidelines was lower (55%) in the 118 urologist-treated CRPC patients. Most physicians (87%) across all specialties considered the presence or absence of bone pain as the most important factor when assessing the risk of bone complications. Bone pain was also reported by the physicians as a main reason for BTA initiation in nearly three-quarters of BTA-treated patients (71% BC, 75% CRPC). Overall, 56% of physicians considered bone pain to be either a bone complication (58% oncologists vs 48% urologists) or a skeletal-related event (53% oncologists vs 68% urologists).
Conclusions
Adherence to ESMO’s guidelines on bone health differed by tumour type and by physician specialty within solid tumour patients treated in routine clinical settings. Despite ESMO’s guidance on bone protection irrespective of symptomatic disease, bone pain appeared to be a trigger for BTA initiation in routine clinical practice.
Clinical trial identification
Amgen study 20150107.
Editorial acknowledgement
Legal entity responsible for the study
Amgen (Europe) GmbH.
Funding
Amgen (Europe) GmbH.
Disclosure
A. Rider: Full / Part-time employment: Adelphi Group Ltd. A.M. Seesaghur: Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen; Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen. K. Lewis: Full / Part-time employment: Adelphi Group Ltd. D. Bluff: Full / Part-time employment: Adelphi Group Ltd. A. Marongiu: Full / Part-time employment, Andrea Marongiu is a contract worker at Amgen. G. Demonty: Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen.
Resources from the same session
2831 - Interleukin-6 as a Predictive Marker for Early Response to Induction Chemotherapy in Acute Myeloblastic Leukaemia
Presenter: Salah Khallaf
Session: Poster Display session 1
Resources:
Abstract
6014 - Impact of FLT3-ITD mutation on post-transplant outcome of adult AML is modified by the concomitant NPM1 mutation and pre-transplant remission status: A report from Taiwan Bone Marrow Transplant Registry (TBMTR)
Presenter: Su-peng Yeh
Session: Poster Display session 1
Resources:
Abstract
2914 - Efficacy endpoints studied in clinical trials for early-onset leukaemia
Presenter: Dylan Said
Session: Poster Display session 1
Resources:
Abstract
4691 - High triglyceride is a major risk factor of DIC and differentiation syndrome in acute promyelocytic leukemia
Presenter: Tomohiro Yamakawa
Session: Poster Display session 1
Resources:
Abstract
4395 - DREAMM 4: A Phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
Presenter: Suzanne Trudel
Session: Poster Display session 1
Resources:
Abstract
2808 - A Phase 1 Study of HMPL-523, a Selective Oral Anti-Spleen Tyrosine Kinase Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Nathan Fowler
Session: Poster Display session 1
Resources:
Abstract
4403 - A Phase 1 Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Jonathon Cohen
Session: Poster Display session 1
Resources:
Abstract
3357 - A global patient-driven Facebook study in a very rare sarcoma: Health-related quality of life in Epithelioid Hemangioendothelioma (EHE) patients
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
2475 - Qualitative study of patients’ experiences of living with and beyond a soft tissue sarcoma diagnosis: the impact of sarcoma specialist services
Presenter: Ana Martins
Session: Poster Display session 1
Resources:
Abstract
2640 - Health-related quality of life issues of patients affected by desmoid-type fibromatosis; experiences from two countries
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract